Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, has been penalized approximately 19.34 million yuan for insider trading and related activities, which includes the confiscation of illegal gains and fines imposed by the China Securities Regulatory Commission [1][2]. Group 1: Penalty Details - Jiang Wei was fined 1.463 million yuan and had illegal gains of 471 million yuan confiscated by the China Securities Regulatory Commission [1][2]. - The penalty is directed at Jiang Wei personally and is stated to have no significant impact on the company's daily operations or financial status [4]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei holds 66.528 million shares, representing 28.6% of Haohai Biological Technology's total shares [4]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [5]. Group 3: Business Developments - Haohai Biological Technology plans to invest 38.3515 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [6]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [6]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.7415 million yuan for 2024, with a loss of 11.9327 million yuan in the first nine months of 2025 [7][8]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological Technology if Ruiji's performance declines [8].

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and related activities, which the company claims will not significantly impact its operations or finances [2][4][6]. Group 1: Penalty Details - Jiang Wei was fined 1,463 million yuan and had 471 million yuan of illegal gains confiscated by the China Securities Regulatory Commission (CSRC) [4][6]. - The penalty is directed at Jiang Wei personally and is stated to be unrelated to the company's operations [6][7]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological, holding 66.528 million shares, which accounts for 28.6% of the total shares [7][8]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [8]. Group 3: Business Developments - Haohai Biological plans to invest 38.35 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [11][12]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [11]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.74 million yuan for 2024, with a loss of 11.93 million yuan in the first three quarters of the current year [12][13]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological if Ruiji's performance declines [13]. Group 5: Market Position - As of December 23, Haohai Biological's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [14].

Core Viewpoint - Haohai Biological Technology (688366) plans to enter the high-value biological amniotic membrane market despite a decline in revenue and net profit, through acquiring a 19.8% stake in Ruijibio [1][3][5]. Group 1: Company Acquisition Details - Haohai Biological signed a share transfer framework agreement to acquire shares from Ruijibio's existing shareholders for a total of approximately 43.91 million yuan [1]. - The acquisition price is set at 4.53 yuan per share, based on the market price before Ruijibio's delisting from the National Equities Exchange and Quotations [3]. - Ruijibio specializes in producing and selling biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. Group 2: Financial Performance - Ruijibio reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4]. - Haohai Biological's revenue for the first three quarters of this year was approximately 1.899 billion yuan, a year-on-year decrease of 8.47%, while net profit was about 305 million yuan, down 10.63% year-on-year [5]. Group 3: Strategic Implications - The investment in Ruijibio is expected to enhance Haohai Biological's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [3]. - The biological amniotic membrane materials possess human-derived biological characteristics, providing a significant technological and material foundation for research and development in regenerative medicine and tissue engineering [3].

Core Viewpoint - Haohai Biological Technology (688366) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.3515 million yuan, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Acquisition - The acquisition will be funded by the company's own capital [1] - The target company, Ruiji Biological, was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction procedures [1] - By investing in Ruiji Biological, the company aims to gain distribution rights for Ruiji's products in China, effectively entering the high-value medical device market of biological amniotic membranes [1] - This acquisition will enhance the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1]